The purchase price is well above Varex’s standing standalone expectations. The $18.90-per-share cash offer is roughly 70% above Varex’s recent pre-announcement trading level of about $11.13, 17% above the published analyst consensus target of approximately $16.17, and 5% above the highest cited target of $18.00. That points to a meaningful strategic or competitive premium rather than a bargain purchase.
| Metric | Filing / external reference | Read-through |
|---|---|---|
| Cash offer per Varex share | $18.90 (Transaction terms) | Above recent trading level and published targets |
| Aggregate transaction value | Approximately $1.1 billion (Transaction terms) | Includes equity awards and net debt as of April 3, 2026 |
| Recent pre-announcement Varex price | Approximately $11.13 | About a 70% offer premium |
| Published analyst consensus target | Approximately $16.17 | Offer is about 17% higher |
| Highest cited analyst target | $18.00 | Offer is about 5% higher |
The strategic rationale is credible but not quantified. Teledyne says Varex adds X-ray tubes, high-radiation detectors, photon-counting detectors, and related imaging products that complement—not materially duplicate—its existing imaging and vacuum-electronics businesses (Transaction rationale). The filing establishes a broader healthcare and industrial-imaging platform, but provides no revenue contribution, cost savings, synergy estimate, or expected return.
For Teledyne shareholders, the economics remain difficult to assess. The deal is cash-funded in principle, but the filing does not disclose financing sources, leverage impact, expected earnings accretion or dilution, closing timing, or valuation multiples (Transaction terms). The stated benefits therefore remain largely management assertions, while the company is committing to pay above both the market price and published standalone valuation expectations.
Net read: strategically sensible, financially under-detailed, and broadly mixed versus expectations. This is a material expansion into adjacent imaging technologies, but the premium is substantial and the filing gives investors no numerical framework for judging whether the purchase price will earn an attractive return. Regulatory approval, integration, customer retention, and synergy execution remain explicit risks (Forward-looking statements).
Read the original 8-K on SEC EDGAR ↗